Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective diligently but unsuccessfully to develop an one-time therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last several shares. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire interview which I came away with an inadequate viewpoint of the business.

Irony of irony, my bad opinion of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how as well as connected intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) and the first new drug application approval ($five million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it has this single therapies in addition to a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an active business with diverse interests albeit focused on leronlimab, several illness sorts, multiple publications and multiple presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I have been asking myself through the very beginning of my interest in this particular company. Judging by way of the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *